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Abstract
Background: The Lives Saved Tool (LiST) has been developed to estimate the impact of health interventions and
can consider multiple interventions simultaneously. Given its increasing usage by donor organizations and national
program planner, we compare the LiST measles model to the widely used World Health Organization’s Department
of Immunization, Vaccines and Biologicals (WHO/IVB) measles model which is used to produce estimates serving as
a major indicator of monitoring country measles epidemics and the progress of measles control.
Methods: We analyzed the WHO/IVB models and the LiST measles model and identified components and
assumptions held in each model. We contrasted the important components, and compared results from the two
models by applying historical measles containing vaccine (MCV) coverages and the default values of all parameters
set in the models. We also conducted analyses following a hypothetical scenario to understand how both models
performed when the proportion of population protected by MCV declined to zero percent in short time period.
Results: The WHO/IVB measles model and the LiST measles model structures differ: the former is a mixed model
which applies surveillance data adjusted for reporting completeness for countries with good disease surveillance
system and applies a natural history model for countries with poorer disease control program and surveillance
system, and the latter is a cohort model incorporating country-specific cause-of-death (CoD) profiles among
children under-five. The trends of estimates of the two models are similar, but the estimates of the first year are
different in most of the countries included in the analysis. The two models are comparable if we adjust the
measles CoD in the LiST to produce the same baseline estimates. In addition, we used the models to estimate the
potential impact of stopping using measles vaccine over a 7-year period. The WHO/IVB model produced similar
estimates to the LiST model with adjusted CoD. But the LiST model produced low estimates for countries with very
low or eliminated measles infection that may be inappropriate.
Conclusions: The study presents methodological and quantitative comparisons between the WHO/IVB and the
LiST measles models that highlights differences in model structures and may help users to better interpret and
contrast estimates of the measles death from the two models. The major differences are resulted from the usage
of case-fatality rate (CFR) in the WHO/IVB model and the CoD profile in the LiST. Both models have their own
advantages and limitations. Users should be aware of the issue and apply as update country parameters as
possible. Advanced models are expected to validate the policy-planning tools in the future.
Introduction
The Lives Saved Tool (LiST) was developed to estimate
the impact of proven interventions on maternal, child
and neonatal mortality. Unlike many existing models,
this tool was designed to estimate the impact of multiple
interventions simultaneously. One can estimate and
compare the impact of intervention options, for example
using resources to scale up birth delivery services versus
increasing coverage of interventions that could be deliv-
ered by community workers. As is outlined in other
papers in this volume and in previous publications [1-3],
LiST is increasingly being used by donor organizations
and national programs as part of the overall planning
process for maternal, neonatal and child health, includ-
ing estimates of the impact of measles vaccine on
under-five mortality. Correspondence: wjchen@jhsph.edu
Department of International Health, Johns Hopkins Bloomberg School of
Public Health, Baltimore, Maryland, USA
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i.e. number of cases, death and disability-adjusted life
years (DALYs), which serves as a routine source of global
measles burden estimates to monitor progress of measles
control [4,5]. Details of the methodology of the estimates,
constructed by experts in World Health Organization’s
Department of Immunization, Vaccines and Biologicals
(WHO/IVB), was published in 2007 along with estimates
of the trends in deaths due to measles over the period
1999-2005 [5]. These estimates along with the yearly
updates on estimates deaths in children under-age five
due to measles [5,6] are a major indicator tracking pro-
gress towards the goal of measles elimination.
In this paper, we compare and contrast the methods,
assumptions and outputs of the LiST and the WHO/
IVB models as they relate to estimating the impact of
measles vaccine on under-five mortality. The paper pro-
vides a brief description of the approach used in the two
models [5,7,8], a comparison of the assumptions and
t h e i rs o u r c e sf o rt h et w om o d e l sa n dac o m p a r i s o no f
the estimates of deaths and the temporal trends from
the two model. The paper concludes with a discussion
of the relative differences between the models and their
strengths and weaknesses.
Model description and method comparison
In this section, we summarize the WHO/IVB model and
LiST model, and contrast the key properties and compo-
nents in the two models.
WHO/IVB measles model
The WHO/IVB model is a mixed model used to esti-
mate country measles burden and to monitor the pro-
gress of measles elimination [5]. To best reflect the
reliability of country disease surveillance system, coun-
tries are first divided into 2 groups according to their
quality of disease reporting system (based on experts’
judgment) and annual coverage of routine measles-con-
taining vaccine (MCV) (Figure 1). Different approaches
of measles burden estimation are applied to each coun-
try grouping. First, countries having high average MCV
coverage (>80%) and good disease reporting systems are
categorized as group 1. Measles cases are derived from
country reports with adjustments of notification effi-
ciency (5%, 20%, and 40%) to accommodate the quality
of reporting system. The lower value indicates a better
reporting system. Group 2 countries are countries that
have poorer disease reporting system or lower MCV
coverage that indicates a poorer disease control pro-
gram. For these countries a natural history model is
applied to obtain number of measles cases and death by
estimating the proportion of population not protected
by MCV immunization under 19 years old [5].
In this paper, we focused on the natural history model
estimating measles death for countries with poorer
reporting systems. The natural history model first iden-
tifies the proportion of population aged 6 month to 19
years old susceptible to measles infection and assumes
that all susceptible subjects would acquire measles infec-
tion by 20
th birthday (Figure 1, details of the model is
available in Additional File 1, Appendix 1). The measles
susceptible population denotes people who do not
receive MCV or who do not develop proper immunity
against measles after vaccination. The WHO/IVB model
can include probable measles outbreaks when country-
reported measles case number is higher than estimated
case number. After identifying the size of susceptible
population (number of cases), the model allocates cases
into 5 age groups using measles case age-specific distri-
butions. Seventy-seven percent measles cases occur to
children aged 6 month to 5 years old.
Measles deaths are produced by the multiplication of
the number of cases in each age group and age-specific
case fatality ratios (CFRs). The WHO/IVB model is illu-
strated as:
Measles Death population mosto   yrs, yr t protected  =× − 61 9 1 (% b by MCV yr t
age i age i age distribution of cases CFR
)
×× (1)
Measles immunization includes two routine MCV
(MCV1, administered at 9-12 month old and MCV2,
usually administered before children entering primary
school) and supplementary immunization activities
(SIA) which children receive independently. SIAs in the
target year and the previous 4 years are incorporated to
account for their effect of reducing measles cases with a
series of adjustment factors (100%, 90%, 80%, 50%, and
25%). The model applies a vaccine effectiveness (VE) of
85% for children receiving 1 dose at age younger than 1
year old, and 95% for children receiving more than 1
dose or receiving vaccines after 1 year old.
One major assumption of the WHO/IVB model is that
the susceptible population of each birth cohort would
acquire measles infection and become cases before their
20
th birthday, and a proportion of cases, which is indi-
cated by age-specific CFR, would die from measles. That
is to say, the model assumes children surviving through
6 month old do not die of other causes, e.g. diarrhea,
non-measles pneumonia, and etc, and will get measles
infection before their 20
th birthday. This assumption is
quite strong since it does not account for the fact that
competing diseases cause more death in children under
5 years old than measles infection does. In two reviews
of estimating global disease burden in children under
5 years old in 2000-2003 and 2008 [9,10], measles infec-
tion accounted for only 6.35% and 1.69% of all-cause
under 5 mortality (not including neonatal mortality).
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of death. In addition, infants younger than 6 month old
are not included since most of them are protected by
maternal antibody against measles infection [11,12]. The
distribution of age of infection is derived from epide-
miologic studies which suggest 77% of the susceptible
children get measles infection before their 5
th birthday
in a country with low and moderate MCV coverage
[13,14]. Because of the high transmissibility of measles,
incidence of measles infection among young children
decreases only when vaccine coverage is high. The age
of infection is shifted to older ages when MCV coverage
is higher than 80% with the proportion of children hav-
ing their measles infection before 5 years old decreases
from 77% to 59%.
Country- and age-specific CFR is another key para-
meter which indicates the proportion of measles deaths
among measles cases for each age group. The values of
country-specific CFRs are derived from national data or
experts’ judge, and are not updated from time to time.
However, CFR varies year by year and across graphical
areas. It is worthy highlighting the impact of the CFR
value on the estimate of measles deaths, e.g. applying a
4% CFR to a given country which has true CFR as 5%
produces a measles death estimate as 80% (4%/5%) of
the true measles death estimates. The model is sensitive
to the variation of CFR. Given the high variation and
uncertainty of country-specific CFR estimates [15], it is
important to make effort on obtaining the accurate CFR
value. Moreover, the model assumes CFR in infants is
twice that in children aged 1-4 years old, and is four
times of that in children aged 5-9 years old. CFR is 0
for children aged 9 years and older. The assumption is
derived by experts’ judge [5,13].
As the authors mentioned in the original publication of
the model, the WHO/IVB model is not perfect, but its
straightforwardness and transparency can help health
authorities understand the epidemics in their country and
evaluate their own measles control program. The model
is not designed to predict the measles burden for country
planning. On the contrary, it aims to understand the cur-
rent status of measles infection by using available
reported and coverage data. The model considers measles
infection as the only cause of death and measles vaccine
as the only intervention; competing causes of death and
other interventions are not considered.
Measles in the LiST software
LiST software is a planning tool allowing users to project
the concurrent impact of maternal, neonatal and child
health interventions, and helps policy-makers to better
allocate the limited resources. LiST is a cohort model
built in the Spectrum Policy Modeling System [7]. The
model applies mortality and health indicators to demo-
graphic projections (2008 UN Population Division), and
models the impact of coverage changes of intervention
on population health outcomes. Country-specific cause-
of-death (CoD) profile indicates proportions of death
caused by measles, diarrhea, pneumonia, and several neo-
natal causes among neonates and child (aged 1 to
59 month) deaths. The profile was constructed by the
WHO Child Health Epidemiology Reference Group
Birth
cohort at 
risk year t
Measles cases allocated 
to each age group by 
applying Age-specific 
case distribution
Country-specific
CFRs
$ multiplying 
age adjustment 
factors
Measles
Susceptible 
population
Total case number
=
(NE) Efficiency on Notificati
cases Reported
NE=5%, 20% and 40% 
X
All countries 
For countries with good 
disease reporting system 
and high measles 
coverage (>=80%)  
MCV coverage: 
MCV1, MCV2 
and SIAs 
Estimated 
Measles
Death, by age 
group
CFRs age 
adjustment factors: 
Age CFRs
<1 2
1-4 1
5-9 0.5 
10-14 0
15-19 0
Age-specific case 
distribution:
Vaccine coverage
Age <80 >=80
<1 12  12 
1-4 65 47 
5-9 18 25 
10-14 4 11 
15-19 1 5
Figure 1 Diagrams of the WHO/IVB measles model and the LiST measles model. $ Country-specific CFR ranges from 0.05% in the
developed countries to 6-8% in the least developed countries.
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international investigations, national reports and local
reports [8,10,16]. The CoD profile is available for year
2000-2003 and 2008 [9,10] and is one of the most impor-
tant components of the LiST module. Detailed method of
LiST estimates were described in the previous publica-
tions [7,8].
Measles infection was one of the causes of death in
the LiST s o f t w a r e .F o u rf a c t o r s ,i n c l u d i n gt w oh e a l t h
outcomes (stunting and wasting) and two interventions
(MCV coverage and the availability of curative vitamin
A supplement in the population), are associated with
measles death (Figure 2). The model considers the con-
current coverage and prevalence changes of the four fac-
tors and estimates the measles death averted with
coverage change of the factors.
In this paper, we consider primarily the impact of
MCV immunization on measles deaths in the LiST
model. The LiST measles model includes two major
parts: baseline estimate and temporal estimates over
time (Figure 3). The baseline estimate of under-five
measles death is determined by the product of measles
CoD proportion, under-five mortality and demographic
projection, and is not affected by the baseline MCV cov-
erage. The accuracy of the measles CoD proportion is
crucial to the measles death estimates in the LiST. Simi-
lar to the CFR in the WHO/IVB model, identify measles
death among all under-five mortality as 4% instead of
the true value 5% would produce the measles death esti-
mates which is 80% of the accurate estimates. Measles
death in the target year (yr t) is determined by the
change of proportion of population protected which is
estimated using MCV coverage change from baseline
year and year t and vaccine effectiveness (VE). In other
words, by the difference between proportions of children
population immune to measles infection by measles
vaccination, see the following simplified formula:
The estimates of the baseline year (year 0):
Measles Death mortality rate population yr 0 yr 0 6-59mos, yr =×    0
measles, yr 0 CoD × (2)
the estimates of the target year (year t):
Measles Death mortality rate population yr t yr t 6-59mos, yr =×    t
measles, yr 0
yr t yr 0
yr 0
CoD
VE MCV MCV
VE MCV
×× −
×−
−×
⎛
⎝
⎜1
1
()
⎜ ⎜
⎞
⎠
⎟ ⎟
(3)
(Here MCVyr t indicates the coverage of MCV in year
t .M o r t a l i t yr a t ei n d i c a t e st h em o r t a l i t yf o rc h i l d r e n
aged 6 months to 5 years old.)
The LiST model incorporated three MCV coverages
including the coverage of first and second routine dose
and coverage of supplementary immunization activity in
each year. Overall MCV coverage is produced by com-
bining the three coverages for each year using the
formula presented in Additional File 1, Appendix 2. The
impact of SIAs can be traced back to four years prior to
the target year [17] but the remaining impact has not
been quantitatively identified. We assume a series of
SIA weighting factor (100%, 88%, 64.7%, 41.2%, and
17.6%) to identify the proportion of children aged 6
month to 5 years old in the target year who receive the
supplementary dose in the target year or anytime in the
previous 4 years. In addition, we assume that the receipt
of routine MCV doses is independent from receipt of
SIAs while the receipt of second routine dose is depen-
dent on receipt of the first one. Different VEs are
Measles vaccine 
Diarrhea
incidence 
Interventions associated 
with Diarrhea: water 
sanitation, personal 
hygiene (baby hygiene) 
practice and water 
connection to home 
Stunting 
IUGR 
Wasting  
Therapeutic feeding  
Complementary 
feeding 
Zinc supplementation 
Vitamin A for 
measles treatment 
Interventions associated 
with IUGR: balanced 
energy 
supplementation, 
micronutrient 
supplementation, 
protection of pregnant 
women from malaria 
Post-Neonatal
Measles 
Mortality
Figure 2 Health status and interventions related to post-neonatal measles mortality in the LiST.
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and age of vaccine receipt that 85% is for 1 routine
dose, 94.2% is for receiving SIA only, and 98% is for
receiving 2 doses [18]. Details are presented in Addi-
tional File 1, Appendix 2.
Another significant characteristic in the LiST measles
model is the ability to incorporate the herd effect of
measles immunization. The herd effect parameter in the
LiST indicates the proportion of measles susceptible
population could be protected by the indirect effect of
the intervention. Based on the result of a systematic
review [18], we assume measles infection is blocked
when 95% of the population is immune to measles
infection by vaccination. The LiST software assumes
that the herd effect of MCV takes effect when 90% of
the population are protected by MCV and achieves total
interruption of transmission when 95% of the popula-
tion immune to measles.
In summary, the LiST measles model captures popula-
tion-specific measles burden by applying an assumed
country-specific cause of death structure which provides
information on the interaction between causes of death
and can incorporate the contribution of multiple inter-
ventions associated with measles death.
Methodology comparison of the two models
As previously explained, WHO/IVB model and the LiST
model differ from their principal approaches of estimat-
ing measles deaths. Table 1 showed parameter-by-para-
meter comparison between the two models. In the
following section, we compare the two models by
estimating the first year (baseline value) and temporal
trend of estimates of measles deaths, in order to illus-
trate the differences between the two models.
The baseline value indicates the estimates of measles
death for the first year of the targeted time-period. In
WHO/IVB model, the estimates are highly dependent
on the CFR and MCV coverage (E. 1), both of which
vary across countries and over time. In the LiST,t h e
CoD profile is the key parameter which incorporates the
effect of competing cause of death in the given country
(E. 2). To sum up, the difference between the estimates
of the first year of the two models depends on how dif-
ferent the estimates derived from natural history model
and the estimated obtained by using CHERG review on
empirical data on child mortality.
The temporal trend of measles death is mainly driven
by the MCV coverage change over time in both models.
The ratios of the measles death of year t to the measles
death of the first year are the similar in both models,
which are equal to the ratio of the susceptible population
of year t to that of the baseline year. The trend differ-
ences between the two models are resulted from the cal-
culation of the proportion of susceptible population
which indicates the population receiving MCV1, MCV2
and SIAs, and the VEs applied. Different discounting fac-
tors of SIAs and assumption of receiving two routine
doses independently may cause at most 15% differences
of the proportion of population immune to measles infec-
tion (Table 1). Furthermore, the LiST model incorporates
the herd effect of MCV, but the WHO/IVB model does
not. The WHO/IVB model incorporates potential country
U5Death yr0:
Population 
projection yr 0 x 
U5MRyr0
Number of measles 
death yr 0 (baseline
estimates) 
% CoD measles, yr0  % CoD measles, yrt 
Coverage change 
from year 0 to year t  
(MCV1, MCV2, and 
SIA)
U5Death yr0:
Population 
projection yr t x
U5MR yrt
Number of 
measles death yr t
Figure 3 Diagram of LiST measles model. Grey blocks:input/known parameters White blocks: output/unknown parameters.
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model could predict the prospective occurrence or the
impact of future measles outbreak.
Considering both the characteristics and differences of
the baseline estimates and temporal trend between two
models, the two models mainly differ between the esti-
mates of the first year (baseline year) with similar tem-
p o r a lt r e n d .O n c ew ea d j u s tb a s e l i n et om a k es i m i l a r
estimates of the first year in both models by adjusting
measles CoD profile in the LiST or CFR in the WHO/
IVB model, we expect to obtain similar estimate series
in both models.
Numerical comparison of estimates based on
historical data between two models
In this section we conducted numerical comparisons to
understand the similarity or differences between the two
models among children under 5 years old in 2000 to
2007. We adjusted parameters to study how different
parameter values affected the estimates in each model
and identified potential determinants associated with the
differences.
Data source
We used historical estimates including MCV coverage,
mortality, CFR, and CoD profile to perform estimates of
both models. We applied population projection from
UN Population Division (revision 2008) in both models.
The WHO Department of Immunization, Vaccines and
Biologicals (IVB) provided the historical MCV coverage
of first routine dose (MCV1), second routine dose
(MCV2) and supplementary immunization activity (SIA)
for 1980-2007. The historical coverage will be publicly
released in the future [19-21]. They also provided coun-
try-specific CFR used in the original WHO estimates [5]
that varied from 0.05% in the developed areas to 8% in
Table 1 Comparison of two models in terms of characteristics and parameters used
WHO/IVB LiST
Model Natural history model Cohort model
Population 6month to 59 months, UN Population Division
projection, revision 2008
6month to 59 months, UN Population Division projection,
revision 2008
Coverage of measles vaccination MCV1, MCV2 and SIAs [WHO/UNICEF vaccine
coverage estimates]
MCV1, MCV2 and SIAs [WHO/UNICEF vaccine coverage
estimates]
Protective effect of SIAs Account for SIAs in the target and the past
4 years
Weighting factor: 100%, 90%, 80%, 50%, and
25%
Account for SIAs in the target and the past 4 years
Weighting factor: 100%, 88%, 64.7%, 41.2%, and 17.6%
Assumption of independence on
vaccine receipt
Assume children receive all three doses
independently
Assume children receive the second routine dose on top of
receiving the first one. Assume receiving routine doses is
independent from receiving SIAs
Coverage being able to
distinguish for different age
group
Model could be modified to account for that if
country-specific information is available
Yes, if country-specific information is available
U5MR Not applicable LiST model uses it for computing number of death [UN
estimates]
Vaccine Effectiveness 85% for dose 1, 95% for dose 2 and SIAs 85% for receiving MCV1 only, 94.2% for receiving SIA only and
98% for receiving more than 1 doses
Herd effect Not applicable Herd effect (HE) kicked in when proportion of population
protected by MCV reached 90%. Twenty percent HE was added
with 1% increment of protection proportion over 90%. HE
reached 100% at 95% of the population directly protected by
the vaccine, and all children who do not receive MCV would
be protected.
Considering other cause of death Not applicable Yes
Country-specific cause-of-death profile
Considering other intervention
associated with measles infection
or mortality
Not applicable Yes
Stunting, wasting, and vitamin A supplement
Country-specific CFRs / CFRs
multiplication factor
Yes
Age-specific CFR, but the value could not
adjust the value with availability of treatments
or other intervention
Not applicable
Age-specific case distribution Yes
Different age distribution of cases owing to
measles coverage higher or lower than 80%
Not applicable
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NNMR and U5MR used in the LiST model were from
T h es t a t eo ft h ew o r l d ’s children, 2000[22]. In the LiST
model, we applied country-specific CoD profile for the
baseline year (year 2000) [10,23]. Proportion of measles
death ranged from <0.1% (Latin American countries,
South Africa, Botswana, and etc) to 8% (Senegal).
Analysis
First, we applied country-specific MCV coverage, mor-
tality, CoD profile and CFR data in the two models to
estimate under-5 measles death between 2000 and 2007.
Sixty-eight LiST-included countries from 6 WHO
regions were included in the analysis (Additional File 1,
Appendix 3). Coverage for interventions other than
MCV remained constant. Second, we adjusted country
specific CoD profiles in the LiST to produce same base-
line measles death to WHO/IVB estimates. We adjusted
measles CoD by multiplying the original measles CoD
with the ratio of WHO/IVB estimates to the LiST esti-
mates for the first year:
adjusted CoD unadjusted CoD
WHO/IVB
LiST
measles measles
yr 0
y
=×
r r 0
.
We obtained the uncertainty bounds of the WHO/
IVB model following the method presented in the
original study of the WHO/IVB model in that the
researchers applied a 5% absolute higher or lower value
of the routine MCV coverage and 20% relative higher
or lower of the original CFR in the WHO/IVB model
[5]. We produced country-specific estimates for 68
countries in the two models and grouped the countries
to present global and 6 regional estimates according to
WHO region categories [24], respectively. Here we
should keep in mind that uncertainty bounds of the
WHO/IVB model were calculated considering variation
o ft h ec o v e r a g eo ff i r s tr o u t i n ed o s ea n dt h eC F R s ,b u t
not incorporating the variation of the coverage of sec-
ond routine dose and SIAs. Uncertainty bounds could
be narrow with low coverage of MCV1 and high cov-
erages of recent SIAs. However, the method has been
used as part of the routine source of measles death
estimates, and is familiar to the public health commu-
nity. So we keep the method and believe it could facili-
tate communication and understanding in the model
comparison.
In addition, we examined the performance of the two
models when overall proportion of population pro-
tected by MCV decreased from the historical value in
2000 to a presumable 0% in 2007. The proportion of
protected population between 2000 and 2007 were the
interpolation between the value in 2000 and 0. We
performed the measles death estimates for the 68
LiST countries, 6 WHO regions and global level,
respectively.
Results
Estimates of measles death based on historical coverage
data in the two models
The LiST model and WHO/IVB estimates using histori-
cal MCV coverage produced estimates with similar
trend in most of the 68 countries in 2000-2007. How-
ever, the estimates were very different at the baseline.
At the global level, WHO/IVB model estimated a total
671,521 measles (uncertainty bounds: 485,248 to
878,341; Figure 4A) death of the 68 countries in 2000
which was higher than the LiST estimates (224,084 in
2000), and the differences between the two models
decreased over time. The estimates of the two models
were much more similar in 2006 and 2007 at the time
coverage had largely increased all over the world. The
updated CHERG review on the under-five mortality esti-
mated around 118,000 annual global measles death in
193 countries in 2008 [9] which is between the LiST
estimates (97,097) of 2007 and the estimate (172,044) in
the WHO/IVB model. The updated CHERG review can
serve as an external reference based on the epidemiolo-
gic studies and country studies. Second, we adjusted the
country-specific CoD profile. The LiST model produced
estimates similar to the WHO/IVB estimates and fell
within the uncertainty bounds of the WHO/IVB esti-
mates in 2000-2005.
The performance of the two models revealed regional
differences. The estimates were qualitatively similar in
both models in other WHO regions, but unadjusted
LiST estimates were lower than WHO/IVB estimates in
AFRO, EMRO, SEARO and WPRO (Figure 4B). In
AMRO and EURO where domestic measles infection
was eliminated, the annual measles deaths were lower
than 100 and were quite similar in both models with
high MCV coverages, low CFRs (<0.05%) or low measles
death among all under-five deaths most of which are
lower than 0.1% (figures not shown). In advance, we
performed CoD-adjusted estimates in LiST to study the
differences between the two models with reduced base-
line difference. The adjusted LiST estimates and WHO/
IVB series were almost identical for AMRO, SEARO
and EURO. In AFRO and EMRO, the estimates were
similar for year 2000 to 2005, but the differences
increased for 2006 and 2007 which were mainly resulted
from the difference of coverage calculation in the two
models, including different weighting factor of SIAs, and
different VE.
In summary, the original LiST estimates were quite
different from WHO/IVB estimates at the first year due
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measles deaths in the baseline year of 2000. However,
the estimates of measles deaths converged over time,
especially 2006-2007, at the time the MCV coverage
increased. When we used the same estimates of measles
deaths for the baseline year of 2000, the two models
produced similar estimates of measles deaths for the
whole time period.
Country-specific estimates from the two models were
qualitatively similar over time, but were different at the
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Figure 4 Comparison of the WHO/IVB estimates and the LiST estimates, 2000-2007 (A) Estimates of measles death in 68 LiST
countries, 2000-2007. Solid line: WHO/IVB estimates Dashed line: LiST estimates Dotted line: CoD adjusted LiST estimates Grey area: uncertainty
bounds of WHO/IVB estimates. (B) Regional estimates of measles death in 2000-2007.
# # Please note the scale of measles death is different
for WPRO. Solid line: WHO/IVB estimates Dashed line: LiST estimates Dotted line: CoD adjusted LiST estimates Grey area: uncertainty bounds of
WHO/IVB estimates.
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Page 8 of 12baseline year in general as was observed at global and
regional estimates (Figures of 68 countries are presented
in Additional File 1, Appendix 4). The CoD-adjusted
LiST estimate series and the WHO/IVB estimates are
alike. However, we observed more discrepancies
between the two models at individual country level, e.g.
Burkina Faso, Cambodia, Democratic Republic of the
Congo, Zambia and etc. Two types of discrepancies
were observed. One mismatch occurred when the CoD-
adjusted LiST estimates and the WHO/IVB estimates
were matching well, but slightly fell outside of the
uncertainty bound of WHO/IVB estimates when intense
SIAs were held in countries, e.g. Afghanistan, Cambodia,
Nepal, Papua New Guinea, and etc. The different
weighting method of SIA coverages in the past 4 years
prior to the target year caused at most 15% difference of
the population protected by routine MCV when a 100%
covered SIA occurred 2 years prior to the target year. In
addition, the method used in the master file of IVB was
modified and was slightly different from the method
described in the Lancet paper.[5] This intra-method dis-
crepancy added up difference between the two models.
On the other hand, countries which had no secondary
immunization opportunity, e.g. India, Liberia, Pakistan
and etc, had almost identical CoD-adjusted LiST esti-
mates and WHO/IVB estimates.
In addition, we found a slight modification of the SIA
weighting factor for 2000, the baseline year, in the
WHO/IVB model from the method presented in the
Lancet paper.[5] Smaller values of weighting factors are
used for SIAs held in 1996-1999. Therefore, the change
resulted in lower baseline coverages for year 2000 in the
WHO/IVB model for countries which held SIAs in 1996
to 1999. The change altered the temporal trend of
measles death in the WHO/IVB model. As a result, the
trend of CoD-adjusted LiST estimates and WHO/IVB
estimates were less alike in these countries, including
Burkina Faso, Democratic Republic of the Congo, Ethio-
pia, Guinea-Bissau, Niger, Philippines, South Africa,
United Republic of Tanzania, Zambia, and Zimbabwe.
What would happen if we scale down measles vaccine
coverage? – estimates of presumable coverage change
We applied the presumable scenario to both models
that MCV protecting population went down from the
proportion in 2000 to 0% in 2007. Global measles death
increased from 680,879 in 2000 to 1,656,922 in 2007 in
the WHO/IVB models, while in the LiST 224,084 in
2000 to 548,478 in 2007 when no measles vaccine is
used in the 68 countries (Figure 5A). The inconsistency
of the baseline estimates are still the major difference
and the CoD-adjusted LiST estimates are quite similar
to the WHO/IVB estimate. However, only 805 measles
death was predicted for 2007 at the time no measles
vaccine was delivered in AMRO where measles had
been eliminated in 2000 (Figure 5B).The LiST model
seemed to produce number of measles death much
lower than expected, especially in countries which
achieved domestic measles elimination in 2000. There-
fore, such few measles death seems inappropriate since
measles epidemic will recur quickly after MCV vaccina-
tion is scaled down given the high transmissibility of
measles virus.
Conclusions
There are five primary conclusions drawn from the
study.
1. The WHO/IVB and the LiST model are compar-
able on measles death estimation from 2000 to 2007,
though the baseline value is the major difference of
the two models
The temporal trends of measles death of the LiST
model from 2000 to 2007 are qualitatively similar to the
WHO/IVB estimates, though the baseline estimates are
significantly different between the two models. When
adjusting for the proportion of measles death among all
under-five deaths (CoD profile) in the LiST model to
yield similar baseline estimates to the WHO/IVB model,
the two series were comparable. The differences
between the CoD-adjusted LiST estimates and WHO/
IVB estimates were mainly resulted from the different
weighting method of SIAs in the two models and also
minor modifications of the WHO/IVB method.
2. Cause-of-death profile is the key assumption in
the LiST model and CFR is critical in the WHO/IVB
model
Inconsistency of the baseline values is the major dif-
ference between the two models to which parameters,
including the CoD-profile in the LiST model and the
CFR in the WHO/IVB model, are the major determi-
nants. CoD profile was reviewed by a group of experts
based on literature, national study and reports [9,10,25].
CFR applied in the WHO/IVB model was review and
determined by experts’ review [5]. Both CoD profile and
country-specific CFR vary with time and geographical
areas. They should be carefully reviewed and updated
properly to reflect correct measles epidemic status in
each country. Imprecision or inaccurate of the para-
meters may introduce high uncertainty of the estimates.
In addition, the WHO/IVB model considering merely
measles infection in the model might have over-esti-
mated the measles death. The results do not suggest
that one model is superior or more accurate than
another. Readers should be aware of the limitations of
the correctness of parameter values and also the
assumptions used in either model when interpreting the
results of the two models and the comparison between
them.
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Page 9 of 123. LiST model does not perform well when measles
vaccination is scaled down to very low coverage in a
short time period
The model underestimates measles death when scaling
down measles vaccination in a short period of time espe-
cially in the countries with elimination of domestic
measles infection. Owing to the high transmissibility of
measles virus, virus could be fast disseminated to the
population and cause disease among susceptible popula-
t i o n ,t h u st h ed i s e a s eb u r d e n ,o rt h ep r o p o r t i o no f
measles death among under-five death, will rapidly
increase. Original CoD profile will not serve as a correct
parameter under the circumstances. We suggest users to
take cautions when they plan to drop the MCV coverage.
4. Multi-intervention associated with measles
infection
The study did not pay much attention on the method
incorporating multi-intervention related to measles
death. The LiST model is able to consider the preva-
lence of stunting, wasting and availability of vitamin A
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Page 10 of 12supplement among under-5 children population when
estimating measles death while the WHO/IVB model
cannot take these factors into account.
5. The decision-making tools are helpful but should
be verified by advanced methods in the future
The two models considered in this study are pragmatic
and user-friendly which allow country policy planners to
plug in and make plan use the country- or population spe-
cific data. They demonstrate the convenience and impor-
tance though the two models are relatively simple and
have their own limitations and uncertainty of estimating
under-five measles death. The variation and uncertainty of
the key parameters might largely change the results.
Therefore, policy-makers who deploy either model to pro-
duce country estimates should be aware of the issue and
use accurate and updated country-specific parameters for
estimation. To accommodate the advantage and disadvan-
tages of these decision-making tools, it is suggested to
develop more advanced models, e.g. dynamic transmission
models which are able to consider the impact of multiple
measles-associated interventions in addition to measles
vaccination and to verify the more programmatic tools by
comparisons to the advanced models. Similar approach
had been taken up in the development and validation of a
program-planning tool which estimates the impact of
male circumcision on HIV prevention [26].
In this study, we compared the LiST model to the
widely accepted WHO/IVB model in estimating the
impact of measles vaccination on the estimates of
measles deaths. There are advantages and disadvantages
to both models, but overall the estimates of the impact
of scaling up measles vaccine on measles mortality were
very similar for the two models. Based on the compari-
son, we suggested verification of these tools with
advanced models should be performed to better under-
stand the validity of the tools. Moreover, it is known
that a new WHO measles model is under construction
and will be applied by IVB in the near future. Further
comparison between the new WHO/IVB model and the
LiST model should be made when the methodology of
the new WHO/IVB model is publically available.
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